Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy

Cancer Letters

Volumn 334, Issue 2, 2013, Pages 346-353

  Maksimenko, Andrei ^a,b   Mougin, Julie ^a,b   Mura, Simona ^a,b   Sliwinski, Eric ^a,b   Lepeltier, Elise ^a,b   Bourgaux, Claudie ^a,b   Lepêtre, Sinda ^a,b   Zouhiri, Fatima ^a,b   Desmaële, Didier ^a,b   Couvreur, Patrick ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIV PARIS SUD   (France)

Author keywords

Gemcitabine; Nanomedicine; Pancreatic cancer; Prodrug; Squalene; Terpene

Indexed keywords

FARNESYLACETYLGEMCITABINE; GEMCITABINE; GERANYLACETYLGEMCITABINE; NANOPARTICLE; POLYISOPRENOYL GEMCITABINE; PRENYLACETYLGEMCITABINE; SQUALENE GEMCITABINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NANOTECHNOLOGY; NONHUMAN; PANCREAS CANCER; PANCREAS CARCINOMA; PARTICLE SIZE; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MCF-7 CELLS; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; NANOPARTICLES; PANCREATIC NEOPLASMS; PRODRUGS; RANDOM ALLOCATION; TERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE; MUS;

EID: 84878239593     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.023     Document Type: Article

References (28)

1. E. Niederlaender, Causes of Death in the EU, EuroStat, 2006.
2. Couvreur P., Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 2006, 23:1417-1451.
3. Wang L., Zhao W., Tan W. Bioconjugated silica nanoparticles: development and applications. Nano Res. 2008, 1:99-115.
4. Couvreur P., Stella B., Reddy H.L., Hillaireau H., Dubernet C., Desmaële D., Lepêtre-Mouelhi S., Rocco F., Dereuddre-Bosquet N., Clayette P., Rosilio V., Marsaud V., Renoir J.-M., Cattel L. Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 2006, 6:2544-2548.
5. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
6. Freitas R.A. The future of nanofabrication and molecular scale devices in nanomedicine. Stud. Health Technol. Inform. 2002, 80:45-59.
7. Hughes G.A. Nanostructure-mediated drug delivery. Nanomed. Nanotechnol. Biol. Med. 2005, 22-30.
8. Xu F.J., Neoh K.G., Kang E.T. Bioactive surfaces and biomaterials via atom transfer radical polymerization. Prog. Polym. Sci. 2009, 34:719-761.
9. Zhou Y. Bio-Inspired Nanomaterials and Nanotechnology 2010, Nova Science Publishers, New York.
10. Linkov I., Satterstrom F.K., Corey L.M. Nanotoxicology and nanomedicine: making hard decisions. Nanomed. Nanotechnol. Biol. Med. 2008, 4:167-171.
11. Zuo L., Wei W., Morris M., Wei J., Gorbounov M., Wei C. New technology and clinical applications of nanomedicine. Med. Clin. North Am. 2007, 91:845-862.
12. Linkov I., Satterstrom F.K., Kiker G.A., Bridges T.S., Benjamin S.L., Belluck D.A. From optimization to adaptation: shifting paradigms in environmental management and their application to remedial decision. Int. Environ. Assess. Manage. 2006, 2:92-98.
13. Couvreur P., Reddy L.H., Mangenot S., Poupaert J.H., Desmaële D., Lepêtre-Mouelhi S., Pili B., Bourgaux C., Amenitsch H., Ollivon M. Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small 2008, 4:247-253.
14. Abbruzzese J.L., Grunewald R., Weeks E.A., Gravel D., Adams T., Nowak B., Mineishi S., Tarassoff P., Satterlee W., Raber M.N. Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. J. Clin. Oncol. 1991, 9:491-498.
15. Grunewald R., Kantarjian H., Du M., Faucher K., Tarassoff P., Plunkett W.J. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J. Clin. Oncol. 1992, 10:406-413.
16. Reddy L.H., Dubernet C., Mouelhi S.L., Marque P.E., Desmaele D., Couvreur P. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J. Control. Release 2007, 124:20-27.
17. Réjiba S., Reddy L.H., Bigand C., Parmentier C., Couvreur P., Hajri A. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine 2011, 7:841-849.
18. Sémiramoth N., Meo C.D., Zouhiri F., Saïd-Hassane F., Valetti S., Gorges R., Nicolas V., Poupaert J.H., Chollet-Martin S., Desmaële D., Gref R., Couvreur P. Self-assembled squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular infections. ACS Nano 2012, 6:3820-3831.
19. Raouane M., Desmaele D., Gilbert-Sirieix M., Gueutin C., Zouhiri F., Bourgaux C., Lepeltier E., Gref R., Ben Salah R., Clayman G., Massaad-Massade L., Couvreur P. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. J. Med. Chem. 2011, 54:4067-4076.
20. Dosio F., Reddy L.H., Ferrero A., Stella B., Cattel L., Couvreur P. Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, characterization, and biological evaluation. Bioconjugate Chem. 2010, 21:1349-1361.
21. Bekkara-Aounallah F., Gref R., Othman M., Reddy L.H., Pili B., Allain V., Bourgaux C., Hillaireau H., Lepêtre-Mouelhi S., Desmaele D., Nicolas J., Chafi N., Couvreur P. Novel PEGylated nanoassemblies made of self-assembled squalenoyl nucleoside analogues. Adv. Funct. Mater. 2008, 18:1-11.
22. Khoury H., Deroussent A., Reddy L.H., Couvreur P., Vassal G., Paci A. Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography-tandem mass spectrometry in human plasma. J. Chromatogr. 2007, 858:71-78.
23. Parshina N.A., Pleteneva T.V., Baikova V.N., Narimanov M.N., Tyulyandin S.A. Quantitative estimation of gemcitabine by HPLC in plasma. Pharm. Chem. J. 2008, 42:37-39.
24. Fujikawa S.M., Chen I.A., Szostak J.W. Shrink-wrap vesicles. Langmuir 2005, 21:12124-12129.
25. Zhang S., Li J., Lykotrafitis G., Bao G., Suresh S. Size-dependent endocytosis of nanoparticles. Adv. Mater. 2009, 21:419-424.
26. Hillaireau H., Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 2009, 66:2873-2896.
27. Bildstein L., Marsaud V., Chacun H., Lepêtre-Mouelhi S., Desmaële D., Couvreur P., Dubernet C. Extracellular-protein-enhanced cellular uptake of squalenoyl gemcitabine from nanoassemblies. Soft Matter 2010, 6:5570-5580.
28. Bildstein L., Dubernet C., Marsaud V., Chacun H., Nicolas V., Gueutin C., Sarasin A., Bénech H., Lepêtre-Mouelhi S., Desmaële D., Couvreur P. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. J. Control. Release 2010, 147:163-170.